'It's a growth play': Catal­ent ac­quires Bris­tol-My­er­s' Eu­ro­pean launch pad, ex­pand­ing glob­al CD­MO ops

Catal­ent is stay­ing on the growth track.

Just two months af­ter com­mit­ting $1.2 bil­lion to pick up Paragon and take a deep dive in­to the siz­zling hot gene ther­a­py man­u­fac­tur­ing sec­tor, the CD­MO is bounc­ing right back with a deal to buy out Bris­tol-My­ers’ cen­tral launch­pad for new ther­a­pies in Eu­rope, ac­quir­ing a com­plex in Anag­ni, Italy, south­west of Rome, that will sig­nif­i­cant­ly ex­pand its ca­pac­i­ty on the con­ti­nent.

There are no terms be­ing of­fered, but this is no small deal. The Anag­ni cam­pus em­ploys some 700 staffers, and Catal­ent is plan­ning to go right in — once the deal clos­es late this year — with a blue­print to build up the op­er­a­tions fur­ther as they ex­pand on oral sol­id, bi­o­log­ics, and ster­ile prod­uct man­u­fac­tur­ing and pack­ag­ing.

This is an un­com­mon deal, Catal­ent CEO John Chimin­s­ki tells me. But it of­fers a short­cut for rapid growth that cuts years out of de­vel­op­ing a green fields project. That’s time Catal­ent doesn’t have as the in­dus­try un­der­goes un­prece­dent­ed ex­pan­sion around the world.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER